Randomized phase II study of docetaxel plus zoledronic acid versus docetaxel in patients with relapsing or refractory non-small cell lung cancer and bone metastasis
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000001098
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
>Previous treatment with docetaxel or zoledronic acid >Regular use of corticosteroidOral complication
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Safety, Response rate, SRE rate, SRE free survival, Over all survival